secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anebulo Pharmaceuticals, Inc. (ANEB)
CIK:        0001815974
Form:       8-K
Filed at:   2024-07-22T23:59:59+00:00
Accession:  0001493152-24-028629
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anebulo awarded up to $1.9M NIDA grant for IV selonabant development
--------------------------------------------------------------------

- Grant from NIDA/NIH up to ~$1.9M over two years for IV selonabant as emergency treatment for acute cannabis-induced toxicities.
- Initial tranche $0.9M awarded; second tranche ~$1M subject to milestone achievements.
- Program targets pediatric cannabis-induced CNS depression, a serious unmet medical need.
- CEO notes grant validates progress and supports IV formulation clinical testing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815974/000149315224028629/0001493152-24-028629-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815974/000149315224028629/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-028629

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer